Your browser doesn't support javascript.
loading
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Wen, Patrick Y; Touat, Mehdi; Alexander, Brian M; Mellinghoff, Ingo K; Ramkissoon, Shakti; McCluskey, Christine S; Pelton, Kristine; Haidar, Sam; Basu, Sankha S; Gaffey, Sarah C; Brown, Loreal E; Martinez-Ledesma, Juan Emmanuel; Wu, Shaofang; Kim, Jungwoo; Wei, Wei; Park, Mi-Ae; Huse, Jason T; Kuhn, John G; Rinne, Mikael L; Colman, Howard; Agar, Nathalie Y R; Omuro, Antonio M; DeAngelis, Lisa M; Gilbert, Mark R; de Groot, John F; Cloughesy, Timothy F; Chi, Andrew S; Roberts, Thomas M; Zhao, Jean J; Lee, Eudocia Q; Nayak, Lakshmi; Heath, James R; Horky, Laura L; Batchelor, Tracy T; Beroukhim, Rameen; Chang, Susan M; Ligon, Azra H; Dunn, Ian F; Koul, Dimpy; Young, Geoffrey S; Prados, Michael D; Reardon, David A; Yung, W K Alfred; Ligon, Keith L.
Afiliación
  • Wen PY; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Touat M; 2 Brigham and Women's Hospital, Boston, MA.
  • Alexander BM; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Mellinghoff IK; 2 Brigham and Women's Hospital, Boston, MA.
  • Ramkissoon S; 1 Dana-Farber Cancer Institute, Boston, MA.
  • McCluskey CS; 2 Brigham and Women's Hospital, Boston, MA.
  • Pelton K; 3 Memorial Sloan Kettering Cancer Center, New York, NY.
  • Haidar S; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Basu SS; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Gaffey SC; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Brown LE; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Martinez-Ledesma JE; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Wu S; 2 Brigham and Women's Hospital, Boston, MA.
  • Kim J; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Wei W; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Park MA; 4 The University of Texas M.D. Anderson Cancer Center, Houston, TX.
  • Huse JT; 4 The University of Texas M.D. Anderson Cancer Center, Houston, TX.
  • Kuhn JG; 5 California Institute of Technology, Pasadena, CA.
  • Rinne ML; 6 David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA.
  • Colman H; 10 Institute for Systems Biology, Seattle, WA.
  • Agar NYR; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Omuro AM; 4 The University of Texas M.D. Anderson Cancer Center, Houston, TX.
  • DeAngelis LM; 7 The University of Texas, San Antonio, San Antonio, TX.
  • Gilbert MR; 1 Dana-Farber Cancer Institute, Boston, MA.
  • de Groot JF; 2 Brigham and Women's Hospital, Boston, MA.
  • Cloughesy TF; 8 Huntsman Cancer Institute and University of Utah, Salt Lake City, UT.
  • Chi AS; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Roberts TM; 2 Brigham and Women's Hospital, Boston, MA.
  • Zhao JJ; 3 Memorial Sloan Kettering Cancer Center, New York, NY.
  • Lee EQ; 3 Memorial Sloan Kettering Cancer Center, New York, NY.
  • Nayak L; 4 The University of Texas M.D. Anderson Cancer Center, Houston, TX.
  • Heath JR; 4 The University of Texas M.D. Anderson Cancer Center, Houston, TX.
  • Horky LL; 6 David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA.
  • Batchelor TT; 9 New York University School of Medicine, New York, NY.
  • Beroukhim R; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Chang SM; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Ligon AH; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Dunn IF; 2 Brigham and Women's Hospital, Boston, MA.
  • Koul D; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Young GS; 2 Brigham and Women's Hospital, Boston, MA.
  • Prados MD; 10 Institute for Systems Biology, Seattle, WA.
  • Reardon DA; 1 Dana-Farber Cancer Institute, Boston, MA.
  • Yung WKA; 11 Massachusetts General Hospital, Boston, MA.
  • Ligon KL; 1 Dana-Farber Cancer Institute, Boston, MA.
J Clin Oncol ; 37(9): 741-750, 2019 03 20.
Article en En | MEDLINE | ID: mdl-30715997
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Morfolinas / Glioblastoma / Terapia Neoadyuvante / Fosfatidilinositol 3-Quinasa / Inhibidores de las Quinasa Fosfoinosítidos-3 / Aminopiridinas / Recurrencia Local de Neoplasia / Antineoplásicos Tipo de estudio: Clinical_trials Idioma: En Revista: J Clin Oncol Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Morfolinas / Glioblastoma / Terapia Neoadyuvante / Fosfatidilinositol 3-Quinasa / Inhibidores de las Quinasa Fosfoinosítidos-3 / Aminopiridinas / Recurrencia Local de Neoplasia / Antineoplásicos Tipo de estudio: Clinical_trials Idioma: En Revista: J Clin Oncol Año: 2019 Tipo del documento: Article